Antilipidemic Drugs

Correct Answer

B — Lomitapide

Rationale

Lomitapide is classified as a microsomal triglyceride transfer protein inhibitor. Microsomal triglyceride transfer protein is required for the assembly of apolipoprotein B-containing lipoproteins — including very low-density lipoprotein and chylomicrons — before they are secreted from the liver and intestine into the bloodstream. By blocking this protein, lomitapide reduces lipoprotein production independent of low-density lipoprotein receptor status, making it effective in patients with homozygous familial hypercholesterolemia who have absent or non-functional low-density lipoprotein receptors. Evinacumab is a monoclonal antibody targeting angiopoietin-like protein 3. Inclisiran is a small interfering ribonucleic acid agent targeting proprotein convertase subtilisin/kexin type 9 messenger ribonucleic acid. Bempedoic acid is an adenosine triphosphate-citrate lyase inhibitor.

Correct Answer

D — Evinacumab

Rationale

Evinacumab is classified as a monoclonal antibody targeting angiopoietin-like protein 3. Angiopoietin-like protein 3 is an endogenous inhibitor of lipoprotein lipase; blocking it with evinacumab enhances triglyceride-rich lipoprotein clearance through a low-density lipoprotein receptor-independent pathway, making evinacumab effective even in patients with homozygous familial hypercholesterolemia who have no functional low-density lipoprotein receptors. Lomitapide is a microsomal triglyceride transfer protein inhibitor. Evolocumab is a monoclonal antibody targeting proprotein convertase subtilisin/kexin type 9, not angiopoietin-like protein 3. Inclisiran is a small interfering ribonucleic acid agent.

Correct Answer

A — Semaglutide

Rationale

Semaglutide is classified as a glucagon-like peptide-1 receptor agonist. Glucagon-like peptide-1 receptor agonists improve insulin sensitivity, modestly reduce triglycerides, and have established cardiovascular outcome benefits in patients with type 2 diabetes. In diabetic dyslipidemia, they are used alongside lipid-specific therapy and contribute to overall cardiovascular risk reduction. Empagliflozin is a sodium-glucose cotransporter-2 inhibitor, a different drug class. Fenofibrate is a peroxisome proliferator-activated receptor-alpha agonist used for triglyceride reduction. Ezetimibe is a Niemann-Pick C1-Like 1 transporter inhibitor used for low-density lipoprotein cholesterol lowering.

Correct Answer

C — Empagliflozin

Rationale

Empagliflozin is classified as a sodium-glucose cotransporter-2 inhibitor. Sodium-glucose cotransporter-2 inhibitors block glucose reabsorption in the renal proximal tubule, improving glycemic control, and have established cardiovascular outcome benefits in patients with type 2 diabetes. In the context of diabetic dyslipidemia, sodium-glucose cotransporter-2 inhibitors modestly reduce triglycerides through improved insulin sensitivity and contribute to overall cardiovascular risk reduction alongside lipid-specific therapy. Semaglutide is a glucagon-like peptide-1 receptor agonist. Lomitapide is a microsomal triglyceride transfer protein inhibitor. Colesevelam is a bile acid sequestrant.

Correct Answer

B — Atorvastatin

Rationale

Atorvastatin is classified as undergoing minimal renal excretion — less than two percent of the drug is excreted unchanged in urine — and therefore requires no dose adjustment at any pre-dialysis stage of chronic kidney disease. This pharmacokinetic property makes atorvastatin the generally preferred high-intensity statin in patients with chronic kidney disease, including those with severely reduced kidney function. Rosuvastatin, while also effective, undergoes proportionally greater renal excretion and accumulates in severe chronic kidney disease; its dose should be capped at 10 milligrams per day when estimated glomerular filtration rate falls below 30 milliliters per minute per 1.73 square meters. Pravastatin also has some renal excretion. Fenofibrate is a fibrate rather than a statin and actually requires dose reduction or avoidance in significant chronic kidney disease.

Correct Answer

D — Amiodarone

Rationale

Amiodarone is classified as a Vaughan Williams Class III antiarrhythmic agent. It is relevant in the context of lipid pharmacology because it is a moderate inhibitor of cytochrome P450 3A4, which can raise plasma concentrations of cytochrome P450 3A4-metabolized statins such as atorvastatin and simvastatin when co-administered. Diltiazem and verapamil are classified as Vaughan Williams Class Four antiarrhythmic agents — calcium channel blockers — and are also cytochrome P450 3A4 inhibitors relevant to statin drug interactions. Itraconazole is an azole antifungal classified as a strong cytochrome P450 3A4 inhibitor, not an antiarrhythmic agent.

Correct Answer

A — Statins, ezetimibe, and proprotein convertase subtilisin/kexin type 9 inhibitors all depend on functional low-density lipoprotein receptors to produce their full effect; in homozygous familial hypercholesterolemia, both receptor alleles carry loss-of-function mutations, leaving few or no functional receptors to respond

Rationale

Statins lower low-density lipoprotein cholesterol primarily by upregulating low-density lipoprotein receptor expression; ezetimibe lowers hepatic cholesterol delivery, triggering the same compensatory receptor upregulation; and proprotein convertase subtilisin/kexin type 9 inhibitors prevent receptor degradation — but all three mechanisms require functional low-density lipoprotein receptors on the hepatocyte surface to produce meaningful low-density lipoprotein clearance from the plasma. In homozygous familial hypercholesterolemia, patients carry two mutant low-density lipoprotein receptor alleles with severely reduced or absent receptor function. When the receptors are absent or severely depleted, upregulating their expression or protecting them from degradation produces only minimal additional clearance, explaining why these agents reduce low-density lipoprotein cholesterol by only 10 to 25 percent in this condition rather than the 60 to 85 percent seen in patients with at least one functional receptor allele. The condition is caused by loss-of-function mutations in the low-density lipoprotein receptor gene in 85 to 90 percent of cases, not gain-of-function proprotein convertase subtilisin/kexin type 9 mutations.

Correct Answer

C — Lomitapide blocks microsomal triglyceride transfer protein in the liver and intestine, preventing the assembly of apolipoprotein B-containing lipoproteins before they are secreted into the bloodstream, reducing low-density lipoprotein production regardless of receptor status

Rationale

Microsomal triglyceride transfer protein is an intracellular enzyme required to load triglycerides onto apolipoprotein B during the assembly of very low-density lipoprotein in hepatocytes and chylomicrons in intestinal cells. Without functional microsomal triglyceride transfer protein, apolipoprotein B-containing lipoproteins cannot be assembled and secreted into the bloodstream. By blocking this assembly step, lomitapide reduces lipoprotein production at the source — an entirely pre-secretion mechanism that does not depend on low-density lipoprotein receptor expression or function. This receptor-independent approach is what makes lomitapide specifically useful in homozygous familial hypercholesterolemia, where the standard strategies of upregulating or protecting low-density lipoprotein receptors are largely ineffective. Lomitapide does not activate macrophage scavenger receptors, does not target angiopoietin-like protein 3, and does not inhibit proprotein convertase subtilisin/kexin type 9 messenger ribonucleic acid.

Correct Answer

B — In advanced heart failure, cardiovascular deaths occur predominantly from pump failure and arrhythmia rather than from atherothrombotic plaque rupture — the mechanism that statin-mediated low-density lipoprotein cholesterol reduction prevents

Rationale

The heart failure statin paradox reflects a fundamental shift in the predominant mechanism of cardiovascular death. In atherosclerotic cardiovascular disease, most cardiovascular deaths result from atherothrombotic plaque rupture and the resulting acute coronary syndromes — events that statins prevent through low-density lipoprotein cholesterol lowering and pleiotropic effects. In advanced heart failure, cardiovascular deaths occur predominantly from pump failure as the failing myocardium loses contractile function, and from malignant arrhythmias arising from the structurally remodeled ventricle. Neither of these mechanisms is prevented by lowering low-density lipoprotein cholesterol, which explains why statins reduce biomarkers of inflammation and lipid levels in heart failure trials yet produce no mortality benefit. Heart failure does not impair statin bioavailability in a clinically meaningful way, statin benefit is not limited by plaque exhaustion, and statins do not worsen cardiac contractility through coenzyme Q10 depletion to a clinically relevant degree.

Correct Answer

D — Diabetic dyslipidemia produces a predominance of small dense low-density lipoprotein particles and elevated triglycerides; in this setting, calculated low-density lipoprotein cholesterol underestimates atherogenic particle burden, while non-high-density lipoprotein cholesterol and apolipoprotein B provide more accurate measures of cardiovascular risk

Rationale

Insulin resistance in type 2 diabetes produces a characteristic dyslipidemia triad: elevated triglycerides, low high-density lipoprotein cholesterol, and a predominance of small dense low-density lipoprotein particles. When triglycerides are elevated, the standard Friedewald calculation of low-density lipoprotein cholesterol loses reliability, and the high number of small dense low-density lipoprotein particles — each carrying less cholesterol per particle than normal-sized particles — means that the total cholesterol carried in low-density lipoprotein underestimates how many atherogenic particles are present. Non-high-density lipoprotein cholesterol captures the cholesterol in all atherogenic apolipoprotein B-containing particles including very low-density lipoprotein, intermediate-density lipoprotein, low-density lipoprotein, and lipoprotein(a). Apolipoprotein B directly counts the number of atherogenic particles, one per particle. Both are more informative treatment targets than low-density lipoprotein cholesterol alone in diabetic patients.

Correct Answer

A — Absolute cardiovascular benefit from statin therapy is greatest in patients with the highest absolute baseline risk; elderly patients with established atherosclerotic cardiovascular disease carry the highest absolute cardiovascular risk, so their absolute benefit from statin therapy exceeds that in younger, lower-risk patients

Rationale

The principle that absolute benefit from preventive therapy is greatest in patients with the highest absolute baseline risk is central to understanding statin use in elderly patients with established atherosclerotic cardiovascular disease. A given relative risk reduction — for example, 25 percent fewer cardiovascular events per 38.7 milligrams per deciliter of low-density lipoprotein cholesterol reduction — translates to a much larger absolute reduction in events when the baseline event rate is high. Elderly patients with established atherosclerotic cardiovascular disease have the highest absolute cardiovascular event rates of any patient group, so even the same relative risk reduction produces substantially more events prevented per year of treatment. This is why guidelines endorse high-intensity statin continuation without an upper age cutoff for secondary prevention, and why discontinuing a well-tolerated statin in this group carries real cardiovascular risk. Statins do not accumulate with age in a clinically meaningful way, pleiotropic benefit is not cumulative over years in the way described, and relative risk reduction from statins does not increase with age.

Correct Answer

C — Atorvastatin undergoes less than two percent renal excretion of unchanged drug and is eliminated primarily by hepatic metabolism and biliary excretion, so declining kidney function does not cause drug accumulation

Rationale

Atorvastatin's elimination route accounts for its safety in chronic kidney disease. Less than two percent of the drug is excreted unchanged in urine; the remainder is metabolized by cytochrome P450 3A4 in the liver and eliminated via biliary excretion. Because renal excretion plays a negligible role in atorvastatin clearance, even severe reductions in glomerular filtration rate do not cause drug accumulation, and no dose adjustment is required at any pre-dialysis stage of chronic kidney disease. In contrast, rosuvastatin undergoes proportionally greater renal excretion and accumulates in severe chronic kidney disease, requiring a dose cap of 10 milligrams per day when estimated glomerular filtration rate falls below 30 milliliters per minute per 1.73 square meters. Atorvastatin is lipophilic rather than hydrophilic, is an active drug rather than a prodrug, and dose-interval extension is not the mechanism that makes it safe in kidney disease.

Correct Answer

B — Fenofibrate reduces renal tubular secretion of creatinine, raising measured serum creatinine without impairing actual glomerular filtration rate — a reversible pharmacokinetic effect that can confuse monitoring rather than indicating true nephrotoxicity

Rationale

Fenofibrate causes a well-recognized reversible rise in serum creatinine by reducing renal tubular secretion of creatinine — the process by which the tubule actively transports creatinine into the urine in addition to glomerular filtration. When tubular secretion is reduced, less creatinine leaves the body per unit time, and serum creatinine rises even though the glomerular filtration rate has not changed. This is a pharmacokinetic effect, not nephrotoxicity. The creatinine rise resolves when fenofibrate is discontinued. In patients with chronic kidney disease, this effect can make it difficult to monitor actual kidney function during therapy. In addition, fenofibrate itself accumulates in severe chronic kidney disease as its own renal excretion is impaired, increasing the risk of myopathy. For these reasons, fenofibrate should be avoided when estimated glomerular filtration rate is below 30 milliliters per minute per 1.73 square meters. Fenofibrate does not cause glomerular injury, does not activate peroxisome proliferator-activated receptor-alpha in tubular cells in a way that increases creatinine production, and does not inhibit hepatic creatine synthesis.

Correct Answer

D — Evinacumab inhibits angiopoietin-like protein 3, an endogenous inhibitor of lipoprotein lipase; blocking angiopoietin-like protein 3 enhances lipoprotein lipase activity and triglyceride-rich lipoprotein clearance through a pathway that does not require low-density lipoprotein receptors

Rationale

Angiopoietin-like protein 3 is an endogenous protein that inhibits lipoprotein lipase, the enzyme responsible for hydrolyzing triglycerides from very low-density lipoprotein and chylomicron particles at the capillary wall. By blocking angiopoietin-like protein 3 with a monoclonal antibody, evinacumab removes this inhibition, allowing lipoprotein lipase to more actively clear triglyceride-rich lipoprotein particles from the plasma. As very low-density lipoprotein particles are hydrolyzed and converted to low-density lipoprotein, increasing their clearance upstream reduces the downstream accumulation of low-density lipoprotein in the plasma. This entire pathway operates independently of low-density lipoprotein receptor expression, which is why evinacumab retains efficacy in patients with homozygous familial hypercholesterolemia who have no functional receptors. Lomitapide — not evinacumab — is the microsomal triglyceride transfer protein inhibitor. Evinacumab does not activate scavenger receptor class B type I and does not target proprotein convertase subtilisin/kexin type 9.

Correct Answer

C — Lomitapide or evinacumab, which lower low-density lipoprotein cholesterol through pathways that do not require functional low-density lipoprotein receptors — reducing lipoprotein production or enhancing clearance by receptor-independent mechanisms

Rationale

In a patient with true receptor-null homozygous familial hypercholesterolemia, all receptor-dependent strategies have been exhausted. Statins and ezetimibe upregulate low-density lipoprotein receptors and proprotein convertase subtilisin/kexin type 9 inhibitors protect those receptors — but when there are no functional receptors, none of these agents can produce meaningful clearance of low-density lipoprotein from the plasma. The two agents specifically approved for homozygous familial hypercholesterolemia work through receptor-independent pathways: lomitapide blocks microsomal triglyceride transfer protein, preventing apolipoprotein B-containing lipoprotein assembly and reducing lipoprotein production regardless of receptor status; evinacumab blocks angiopoietin-like protein 3, enhancing lipoprotein lipase-mediated clearance of triglyceride-rich particles through a pathway that also does not require low-density lipoprotein receptors. Both produce approximately 40 to 50 percent additional low-density lipoprotein cholesterol reduction even in receptor-negative patients. Bile acid sequestrants also depend on receptor upregulation. Inclisiran protects low-density lipoprotein receptors from proprotein convertase subtilisin/kexin type 9 degradation — ineffective when receptors are absent. Switching between monoclonal antibodies targeting proprotein convertase subtilisin/kexin type 9 does not provide additional benefit in receptor-null patients.

Correct Answer

A — Continue atorvastatin — the heart failure statin paradox applies to initiating statins solely for heart failure, not to continuing statins in a patient with established atherosclerotic cardiovascular disease, where secondary prevention benefit is maintained

Rationale

The heart failure statin paradox — the finding that statins do not reduce all-cause mortality in dedicated heart failure trials — does not negate the secondary prevention benefit in patients who also have established atherosclerotic cardiovascular disease. Current guidelines specify three clinical rules: continue statins in heart failure patients who have established atherosclerotic cardiovascular disease; do not initiate statins de novo in heart failure patients solely to treat the heart failure; and do not discontinue a well-tolerated statin in a stable heart failure patient currently taking one. This patient has both a prior myocardial infarction and heart failure — the secondary prevention indication for his statin is independent of the heart failure. Discontinuing a well-tolerated statin in a patient with established atherosclerotic cardiovascular disease and heart failure removes documented secondary prevention benefit without a pharmacological rationale. Dose reduction and substitution with ezetimibe are not indicated here and are not supported by the evidence base for this specific clinical situation.

Correct Answer

B — In a frail primary prevention patient with limited life expectancy and high polypharmacy burden, the time-to-benefit horizon of statin therapy may exceed her expected lifespan, and a randomized trial of statin discontinuation in this population demonstrated safety without excess cardiovascular events over 12 months

Rationale

Deprescribing of statins is evidence-supported in elderly patients with limited life expectancy, advanced frailty, and significant polypharmacy who are taking statins for primary prevention — exactly the scenario this patient presents. Statin therapy generally requires two to five years of treatment before cardiovascular benefit accrues; in a patient with advanced frailty at age 82, remaining life expectancy may not cover this time-to-benefit horizon. A cluster-randomized trial of statin discontinuation in patients aged 75 and older with limited life expectancy on primary prevention statins demonstrated that discontinuation was safe, reduced pill burden, and improved quality-of-life measures without excess cardiovascular events over 12 months. The deprescribing framework considers the primary versus secondary prevention indication, estimated life expectancy against the time-to-benefit horizon, frailty and functional status, polypharmacy burden, and patient preferences. Statins are not contraindicated at age 80, do not accumulate in elderly patients due to renal clearance in a clinically meaningful way, and there is no plaque stabilization plateau after which benefit ceases.

Correct Answer

D — Atorvastatin undergoes less than two percent renal excretion and does not require dose adjustment in chronic kidney disease, allowing full high-intensity dosing at 40 to 80 milligrams daily — unlike rosuvastatin, which accumulates in severe chronic kidney disease and must be capped at 10 milligrams per day

Rationale

The pharmacokinetic difference between atorvastatin and rosuvastatin in chronic kidney disease is clinically decisive in this patient. Rosuvastatin undergoes proportionally greater renal excretion than atorvastatin, and in patients with estimated glomerular filtration rate below 30 milliliters per minute per 1.73 square meters, rosuvastatin accumulates to a degree that requires a dose cap of 10 milligrams per day — which is only moderate-intensity statin therapy and is insufficient to reach the low-density lipoprotein cholesterol target in a secondary prevention patient. Atorvastatin, by contrast, undergoes less than two percent renal excretion of unchanged drug and is eliminated almost entirely by hepatic metabolism and biliary excretion. Kidney function has no clinically meaningful impact on atorvastatin clearance, and no dose adjustment is required at any pre-dialysis chronic kidney disease stage. Switching to atorvastatin 40 or 80 milligrams daily allows full high-intensity therapy without accumulation risk, providing the greater low-density lipoprotein cholesterol reduction this patient needs. Atorvastatin is lipophilic, not hydrophilic, and no dose reduction is required when switching — full doses are safe.